eTheRNA Immunotherapies Advances In-Vivo mRNA Cancer Immunotherapy into First Oncology Clinical Studies – PR Newswire (press release)
|
eTheRNA Immunotherapies Advances In-Vivo mRNA Cancer Immunotherapy into First Oncology Clinical Studies
PR Newswire (press release) TriMix-MEL is a rationally designed, investigational immunotherapy comprising eTheRNA's core TriMix mRNAs, which include a unique combination of three mRNAs encoding proteins that act highly synergistically via three different pathways for the optimal … |
